Legal
Disclosures
Last updated: May 2026
Investigational Product Notice
F14 is an investigational product under clinical development and has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. The safety and efficacy of F14 have not been fully established.
Forward-Looking Statements
This website contains forward-looking statements regarding Arthritis Innovation Corporation (“AIC”), including statements related to product development, clinical trials, regulatory strategy, commercialization plans, business strategy, market opportunity, and future performance. These statements are based on current expectations, assumptions, and beliefs and are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. AIC undertakes no obligation to update forward-looking statements except as required by applicable law.
No Offer or Solicitation
Nothing contained on this website constitutes an offer to sell or a solicitation of an offer to purchase any securities of Arthritis Innovation Corporation. Any such offer or solicitation may only be made through formal offering documents and in compliance with applicable securities laws.
Clinical Data Disclosure
Clinical, preclinical, pharmacokinetic, and other scientific data referenced on this website are based on studies conducted to date and are subject to further analysis and regulatory review. Results from prior studies may not be predictive of future clinical outcomes. Data referenced on this website may include unpublished data on file with AIC.
Regulatory Pathway Disclosure
References to AIC’s intended regulatory strategy, including the 505(b)(2) pathway, reflect the company’s current development plans and regulatory interactions. Regulatory review and approval decisions remain solely within the discretion of applicable regulatory authorities, and there can be no assurance that any product candidate will receive approval.
Market and Financial Projections
Any market size estimates, addressable market figures, commercial opportunity assessments, or financial projections referenced on this website are based on internal analyses, third-party sources, and current assumptions believed to be reasonable at the time presented. Actual market conditions and future results may differ materially.
NOPAIN Act
References to the NOPAIN Act or potential reimbursement pathways are based on current legislation, guidance, and market assumptions, all of which are subject to change. There can be no assurance that F14 will qualify for or benefit from any specific reimbursement program or policy.
Contact
For questions regarding these disclosures, contact Arthritis Innovation Corporation at [email protected].